The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.

I have a 46-year-old female patient with a well-differentiated papillary endocervical adenocarcinoma, surgically staged as IB1. All margins are free, and all pelvic, iliac, obturator, and aortic nodes ...

Cohort profile: African Collaborative Center for Microbiome and Genomics Research (ACCME) study. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a ...